Company intelligence / Profile preview

SphingoTec

Hennigsdorf, Brandenburg, Germany

Ownership: Private
Development stage: Other

Overview

SphingoTec has developed and commercialized proprietary biomarker-based diagnostic assays for acute and critical care indications; their biomarkers, such as penKid for kidney function and bio-ADM for endothelial function, are available as research-use (RUO) kits and are out-licensed for clinical diagnostic applications. Clinical results demonstrate improved early risk stratification for critically ill patients, enabling better clinical decision-making.

Therapeutic areas: NephrologyMetabolic DisordersInfectious DiseasesCardiovascularOncology
Modalities: DeviceProtein (biomarker-based diagnostics using antibody and protein-based IVD assays)
Industry: Protein Biomarker Diagnostics

Partnerships

Global IVD and pharma companiesLeading academic and non-academic medical centers

Beyond the preview

Go deeper on SphingoTec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SphingoTec.

Explore the full profile